These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 15047211)

  • 41. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma.
    Gehrig PA; Van Le L; Olatidoye B; Geradts J
    Cancer; 1999 Nov; 86(10):2083-9. PubMed ID: 10570435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Tomsová M; Melichar B; Sedláková I; Steiner I
    Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The significance of Wilms Tumor Gene (WT1) and p53 expression in curettage specimens of patients with endometrial carcinomas.
    Matalka I; Obeidat B; Mohtaseb A; Awamleh A
    Pathol Res Pract; 2013 Jan; 209(1):19-23. PubMed ID: 23207289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer.
    Papantoniou VJ; Souvatzoglou MA; Valotassiou VJ; Louvrou AN; Ambela C; Koutsikos J; Lazaris D; Christodoulidou JK; Sotiropoulou MG; Melissinou MJ; Perperoglou A; Tsiouris S; Zerva CJ
    Breast Cancer Res; 2004; 6(2):R56-62. PubMed ID: 14979918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M; Zhao L; Shen D; Li X; Wang J; Wei L
    Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The prognostic significance of progesterone receptor level in endometrial cancer].
    Nyholm HC; Christensen IJ; Nielsen AL
    Ugeskr Laeger; 1997 Jan; 159(5):601-4. PubMed ID: 9045451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. bcl-2 and p53 in endometrial adenocarcinoma.
    Taskin M; Lallas TA; Barber HR; Shevchuk MM
    Mod Pathol; 1997 Jul; 10(7):728-34. PubMed ID: 9237185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of the apoptosis-related genes Bcl-2 and p53 in clinical samples from endometrial carcinoma patients.
    González-Rodilla I; Verna V; Muñoz AB; Estévez J; Boix M; Schneider J
    Anticancer Res; 2011 Dec; 31(12):4191-3. PubMed ID: 22199279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of p53, Ki-67, and CD31 in the vaginal margins of radical hysterectomy in patients with stage IB carcinoma of the cervix.
    Silva-Filho AL; Traiman P; Triginelli SA; Reis FM; Pedrosa MS; Miranda D; Abreu ES; Macarenco RS; Cunha-Melo JR
    Gynecol Oncol; 2004 Dec; 95(3):646-54. PubMed ID: 15581977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma.
    Honig A; Schaller N; Dietl J; Backe J; Kammerer U
    Anticancer Res; 2005; 25(3A):1747-53. PubMed ID: 16033094
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Contribution of immunohistochemical profile in assessing histological grade of endometrial cancer.
    Canlorbe G; Laas E; Bendifallah S; Daraï E; Ballester M
    Anticancer Res; 2013 May; 33(5):2191-8. PubMed ID: 23645775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
    González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
    Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The value of searching for additional prognostic factors in combination with Nottingham Prognostic Index in breast carcinoma patients].
    Jakić-Razumović J; Corić M; Vrbanec D; Babić D; Hlupić L; Belev B
    Lijec Vjesn; 2005; 127(1-2):3-7. PubMed ID: 16145866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors.
    Pizer ES; Lax SF; Kuhajda FP; Pasternack GR; Kurman RJ
    Cancer; 1998 Aug; 83(3):528-37. PubMed ID: 9690546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
    Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of erythropoietin expression in human endometrial carcinoma.
    Acs G; Xu X; Chu C; Acs P; Verma A
    Cancer; 2004 Jun; 100(11):2376-86. PubMed ID: 15160341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
    Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
    J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.